Liver Transplantation News and Research RSS Feed - Liver Transplantation News and Research

Study finds way to increase liver cancer screening rates among at-risk cirrhosis patients

Study finds way to increase liver cancer screening rates among at-risk cirrhosis patients

Proactive outreach to cirrhosis patients in a safety net health system successfully doubled their screening rates for liver cancer, UT Southwestern Medical Center researchers found. [More]
Researchers uncover prevalence of anxiety and depression in young people with chronic liver diseases

Researchers uncover prevalence of anxiety and depression in young people with chronic liver diseases

Researchers have found that many teens and young adults with chronic liver conditions suffer from depression and anxiety, which can have considerable impacts on their emotional and physical health. [More]
Scientists generate functional tissue-engineered liver from adult stem and progenitor cells

Scientists generate functional tissue-engineered liver from adult stem and progenitor cells

A research team led by investigators at The Saban Research Institute of Children's Hospital Los Angeles has generated functional human and mouse tissue-engineered liver from adult stem and progenitor cells. [More]
Cell-free DNA test could help identify liver transplant patients with acute rejection

Cell-free DNA test could help identify liver transplant patients with acute rejection

Today, researchers presented findings at the 68th AACC Annual Scientific Meeting that DNA found circulating in the bloodstream—known as cell-free DNA—can be used to identify liver transplant patients with acute rejection with greater accuracy than conventional liver function tests. [More]
Study shows how Medicaid expansion affects health insurance coverage of liver transplant recipients

Study shows how Medicaid expansion affects health insurance coverage of liver transplant recipients

Researchers have found that Medicaid expansion increased Medicaid enrollment among people who received liver transplants funded by commercial insurance. The findings are published inLiver Transplantation. [More]
Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis). [More]
Scientists use new technique to repair fibrotic liver cells within the organ

Scientists use new technique to repair fibrotic liver cells within the organ

Advances in stem cell research have made it possible to convert patients' skin cells into heart cells, kidney cells, liver cells and more in the lab dish, giving researchers hope that one day such cells could replace organ transplantation for patients with organ failure. [More]
Changes in intestinal microbiota linked to primary sclerosing cholangitis

Changes in intestinal microbiota linked to primary sclerosing cholangitis

Primary sclerosing cholangitis, also known as PSC, is a liver disease with no effective medical treatment. Liver transplantation is the only proven long-term treatment of PSC, although only a fraction of individuals with PSC will ultimately require it. [More]
Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology. [More]
Increasing number of sickest liver transplant candidates delisted from wait list, study finds

Increasing number of sickest liver transplant candidates delisted from wait list, study finds

The sickest liver transplant candidates should be first in line when a donor liver becomes available, but transplant centers are increasingly removing these individuals from the waiting list, considering them "too sick to transplant," an analysis of nationwide transplant data finds. The study appears online as an "article in press" on the Journal of the American College of Surgeons website in advance of print publication. [More]
Researchers find prevalence of steatosis in liver transplant recipients

Researchers find prevalence of steatosis in liver transplant recipients

Researchers have characterized the prevalence and risk factors of fatty liver disease in patients who undergo liver transplantation. The findings, which are published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases, could have important implications for safeguarding transplant recipients' health. [More]
Analysis reveals improved survivorship for acute liver failure patients

Analysis reveals improved survivorship for acute liver failure patients

More patients hospitalized with acute liver failure - often the result of acetaminophen overdose - are surviving, including those who receive a liver transplant and those who don't, an analysis led by a UT Southwestern Medical Center researcher showed. [More]
Renal risk factors for NA-treated HBV patients identified

Renal risk factors for NA-treated HBV patients identified

A South Korean research team has identified several clinical and medical factors associated with renal function decline in patients with chronic hepatitis B virus infection treated with oral nucleos(t)ide analogues. [More]
Modified protein appears to reverse liver fibrosis, cirrhosis in rats

Modified protein appears to reverse liver fibrosis, cirrhosis in rats

A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers. [More]
Experimental nanoparticle therapy shows promise for fighting primary liver cancer

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report. [More]
EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Bristol-Myers Squibb today announced that the European Commission has approved the expanded use of Daklinza, a first-in-class oral, once-a-day pill used in combination with other treatments as an option for adult patients with chronic hepatitis C virus infection who are co-infected with HIV or who have had a prior liver transplant. [More]
Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus. [More]
New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

A study by IRB Barcelona and IDIBAPS reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis. [More]
Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the study was co-led by investigators at Beth Israel Deaconess Medical Center and Intermountain Medical Center and published online Nov. 17 in The New England Journal of Medicine. [More]
Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Nearly 50 percent of Medicaid patients infected with chronic hepatitis C whose doctors had prescribed newer, life-saving antiviral drugs were denied coverage to the therapies because they weren't considered "a medical necessity" or because the patients tested positive for alcohol/drugs, among other reasons, according to new Penn Medicine research. [More]
Advertisement